Bioporto AS (FRA:2P4) Moat Score: 0/10 (As of Jul. 02, 2026)


FRA:2P4 Bioporto AS FRA:2P4
66 GF Score
Price €0.13
GF Value €0.15
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Moat Score?

Bioporto AS has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Bioporto AS has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bioporto AS might have No Moat - No discernible moat.

Bioporto AS  (FRA:2P4) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bioporto AS Moat Score Related Terms

FRA:2P4
66GF Score
Bioporto AS FRA:2P4
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioporto AS (FRA:2P4) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of €0.13 is trading 13.7% below its estimated GF Value™ of €0.15.

Key valuation signals for FRA:2P4:

  • Moat Score: 0
  • GF Value™: €0.15 vs. price of €0.13 (13.7% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the FRA:2P4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges BIOPOR:Denmark
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score

Get the complete analysis for FRA:2P4

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.15
GF Value